Method for studying on prostate cancer reoccurrence and metastasis

Abstract

The invention discloses a method for studying on prostate cancer reoccurrence and metastasis, not useful in diagnosing and treating diseases. The method is characterized by including: using paraffin-embedded tissue samples containing prostate tissues, making the samples into HE (hematoxylin and eosin) stained tissue slices, making the tissue slices into microarray tissue chips, subjecting the microarray tissue chips to immunohistochemical staining, observing under a microscope, acquiring stained cell scores according to stained cell percentage ranges of the samples, acquiring a positive staining strength coefficient according to staining strength, multiplying the stained cell scores by the positive staining strength coefficient to obtain protein expression level of MS4A8B gene, and determining prostate cancer reoccurrence rate and metastasis rate according to the protein expression level of MS4A8B gene or by subjecting the protein expression level of MSA8B gene and a proliferation index of MS4A8B gene to correlation analysis. Prostate cancer reoccurrence and metastasis are studied herein by detecting the protein expression level and proliferation index of prostate cancer gene in the tissue samples to be detected.

Description

[0001] This application is a divisional application with an application date of June 24, 2013, an application number of 201310253540.6, and an invention title of "Use and method of prostate cancer gene markers in marking prostate cancer recurrence and metastasis". technical field [0002] The present invention relates to compositions and methods for cancer diagnosis, research and treatment, including but not limited to cancer markers. More specifically, the present invention relates to gene markers useful as markers of prostate cancer recurrence and metastasis. Background of the invention [0003] Prostate cancer is the malignant tumor with the highest incidence rate in European and American men, and it ranks second in the male tumor mortality rate in the United States, second only to lung cancer. According to statistics, there were 241,740 newly diagnosed prostate cancer patients in the United States in 2012, accounting for 29% of all new tumor patients; 28,170 people died ...

AI Technical Summary

Problems solved by technology

However, due to the high expression rate in the benign prostate epithelium, the value of PSMA in predicting the progression of prostate cancer is greatly reduced.

[0016] However, unlike other tumors, prostate cancer often coexists with multiple histopathological forms and even mixes with normal glands. This unique feature makes the research on tissue markers for the prediction of prostate cancer progression and recurrence very difficult. Despite huge investment, little progress has been made.

Images